Adult atopic dermatitis: new and emerging therapies
- 9 August 2018
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 11 (9) , 867-878
Abstract
Adult atopic dermatitis (AD) is very difficult to manage. Indeed, AD in adults is frequently refractory to topical treatment, especially with regards to the persistent form. Therefore, long-term treatment with oral immunosuppressive therapy is often required to control the burden of the disease, prevent flare-ups and achieve better patient quality of life outcomes. Areas covered: In the last decade the better understanding of AD pathogenesis has been used to improve treatment strategies with many emerging therapeutics options. Epidermal barrier impairment often plays the initial role in the initiation of the disease. Moreover, T helper 2 cytokines interleukin (IL)-4 and IL-13 and their downstream effects are prominent in AD, with pleiotropic effects on the innate and adaptive immune system. Targeting these cells, their products or receptors appears to be a reasonable therapeutic strategy. Expert commentary: In the next years, many therapeutic options for adult AD will be available. Clinical trials showed that JAK inhibitors, PDE-4 inhibitors and monoclonal antibodies against some IL (IL-4, IL 13, IL-17, IL-22, IL-31) seem to be the most promising drugs, but dermatologists will have to evaluate their effectiveness and safety in clinical practice.Keywords
Funding Information
- not funded
This publication has 85 references indexed in Scilit:
- Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitisJournal of Allergy and Clinical Immunology, 2013
- The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitisJAK-STAT, 2013
- Janus kinase inhibitors in autoimmune diseasesAnnals of the Rheumatic Diseases, 2013
- JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated DiseaseImmunity, 2012
- Structures and biological functions of IL-31 and IL-31 receptorsCytokine & Growth Factor Reviews, 2008
- Antimicrobial Activity of Omiganan Pentahydrochloride against Contemporary Fungal Pathogens Responsible for Catheter-Associated InfectionsAntimicrobial Agents and Chemotherapy, 2008
- Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6Clinical Immunology, 2008
- Cytokine modulation of atopic dermatitis filaggrin skin expressionJournal of Allergy and Clinical Immunology, 2007
- Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 1993
- Elevated umbilical cord blood leukocyte cyclic adenosine monophosphate-phosphodiesterase activity in children with atopic parentsJournal of the American Academy of Dermatology, 1984